Takeshi Nagasaka

List of Publications by Year
in descending order

41	2,323	361045 20	344852 36
papers	citations	h-index	g-index

47	47	47	4003
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study. European Journal of Cancer, 2022, 169, 166-178.	1.3	0
2	Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations. Clinical Epigenetics, 2021, 13, 117.	1.8	8
3	Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer. Future Science OA, 2021, 7, FSO757.	0.9	1
4	Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases. Langenbeck's Archives of Surgery, 2021, , 1.	0.8	1
5	Prognostic Nutritional Index as a Predictor of Postoperative Outcome in Patients Aged 85ÂYears or Older After Colorectal Cancer Surgery. Indian Journal of Surgery, 2020, 82, 874-878.	0.2	0
6	Natural history of epithelioid hemangioendothelioma that progressed over 20 years. Pediatric Blood and Cancer, 2020, 67, e28261.	0.8	0
7	Upregulation of microRNAâ€'31 is associated with poor prognosis in patients with advanced colorectal cancer. Oncology Letters, 2020, 19, 2685-2694.	0.8	6
8	Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency. Liver Cancer, 2019, 8, 239-254.	4.2	14
9	Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). British Journal of Cancer, 2019, 121, 222-229.	2.9	37
10	Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study). International Journal of Clinical Oncology, 2019, 24, 1223-1230.	1.0	9
11	Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC) Tj ETQq1 1 0.784314 rgBT /Overlock	3.24	1
12	PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. Scientific Reports, 2019, 9, 4633.	1.6	37
13	Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer. Cancer Letters, 2019, 444, 127-135.	3.2	40
14	Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy. International Journal of Cancer, 2019, 144, 2169-2180.	2.3	22
15	Analysis of UGT1Aâ€™s polymorphisms and RAS: RAF mutations based on phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 565-565.	0.8	0
16	A multicenter singleâ€'arm Phase II clinical trial of secondâ€'line FOLFIRI plus panitumumab after firstâ€'line treatment with FOLFOX plus panitumumab for initial RAS wildâ€'type colorectal cancer with evaluation of circulating tumor DNA: A protocol study. Oncology Letters, 2018, 17, 1980-1985.	0.8	3
17	Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles. Oncotarget, 2018, 9, 16477-16488.	0.8	23
18	Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. PLoS ONE, 2018, 13, e0195655.	1.1	30

#	Article	IF	Citations
19	Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors. Journal of Translational Medicine, 2018, 16, 5.	1.8	21
20	AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. JCI Insight, 2018, 3, .	2.3	91
21	Comparison of outcomes between symptomatic and asymptomatic patients with colorectal cancer: a propensity score-matched analysis of surgical invasiveness, medical costs and oncological outcomes. BMJ Open Gastroenterology, 2017, 4, e000146.	1.1	7
22	BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stageÃ¯Â¿Â½IV colorectal cancer. Oncology Letters, 2017, 15, 2195-2201.	0.8	6
23	Adenocarcinoma in the jejunum 20 years after surgery for familial adenomatous polyposis. Okayama Igakkai Zasshi, 2017, 129, 111-114.	0.0	0
24	Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C³) study. BMJ Open, 2016, 6, e011454.	0.8	6
25	Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1557-1569.	1.2	5
26	The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma â€“ a report of a case. BMC Medical Genetics, 2015, 16, 1.	2.1	24
27	Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics. Gut, 2015, 64, 627-635.	6.1	27
28	Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients. World Journal of Gastroenterology, 2014, 20, 17796-17803.	1.4	28
29	Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. Journal of Hepato-Biliary-Pancreatic Sciences, 2013, 20, 223-233.	1.4	50
30	Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer. Journal of the National Cancer Institute, 2013, 105, 849-859.	3.0	425
31	Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Medica Okayama, 2011, 65, 169-77.	0.1	18
32	An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers. PLoS ONE, 2010, 5, e9393.	1.1	136
33	Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. Okayama Igakkai Zasshi, 2010, 122, 107-112.	0.0	1
34	Somatic Hypermethylation of MSH2 Is a Frequent Event in Lynch Syndrome Colorectal Cancers. Cancer Research, 2010, 70, 3098-3108.	0.4	167
35	Fecal MicroRNAs as Novel Biomarkers for Colon Cancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1766-1774.	1.1	310
36	Analysis of Fecal DNA Methylation to Detect Gastrointestinal Neoplasia. Journal of the National Cancer Institute, 2009, 101, 1244-1258.	3.0	122

#	Article	IF	Citations
37	Methylation pattern of theO6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. International Journal of Cancer, 2008, 122, 2429-2436.	2.3	62
38	Mutations in Both KRAS and BRAF May Contribute to the Methylator Phenotype in Colon Cancer. Gastroenterology, 2008, 134, 1950-1960.e1.	0.6	114
39	The CpG Island Methylator Phenotype and Chromosomal Instability Are Inversely Correlated in Sporadic Colorectal Cancer. Gastroenterology, 2007, 132, 127-138.	0.6	264
40	Detection of fecal DNA methylation for colorectal neoplasia: does it lead to an optimal screening test?. Acta Medica Okayama, 2006, 60, 249-56.	0.1	5
41	Colorectal Cancer With Mutation in BRAF, KRAS, and Wild-Type With Respect to Both Oncogenes Showing Different Patterns of DNA Methylation. Journal of Clinical Oncology, 2004, 22, 4584-4594.	0.8	202